Found: 11
Select item for more details and to access through your institution.
Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open‐Label, 1‐Sequence, Crossover Studies.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 4, p. 486, doi. 10.1002/cpdd.1076
- By:
- Publication type:
- Article
Population pharmacokinetics of roxadustat in Japanese dialysis‐dependent chronic kidney disease patients with anaemia.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 2, p. 787, doi. 10.1111/bcp.15023
- By:
- Publication type:
- Article
Pilocarpine‐Induced Effects on Salivary Secretion as a Pharmacological Biomarker for Cholinergic Parasympathetic Activation.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 1, p. 25, doi. 10.1002/cpdd.1048
- By:
- Publication type:
- Article
An Open‐Label, Single‐Dose, Human Mass Balance Study of Amenamevir in Healthy Male Adults.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 5, p. 595, doi. 10.1002/cpdd.630
- By:
- Publication type:
- Article
Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
- Published in:
- Clinical Drug Investigation, 2016, v. 36, n. 9, p. 743, doi. 10.1007/s40261-016-0422-y
- By:
- Publication type:
- Article
The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein.
- Published in:
- Clinical Pharmacology in Drug Development, 2014, v. 3, n. 3, p. 194, doi. 10.1002/cpdd.93
- By:
- Publication type:
- Article
Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects.
- Published in:
- Biopharmaceutics & Drug Disposition, 2013, v. 34, n. 8, p. 431, doi. 10.1002/bdd.1858
- By:
- Publication type:
- Article
The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.
- Published in:
- British Journal of Clinical Pharmacology, 2013, v. 75, n. 2, p. 440, doi. 10.1111/j.1365-2125.2012.04346.x
- By:
- Publication type:
- Article
Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling.
- Published in:
- AAPS Journal, 2005, v. 7, n. 3, p. E532, doi. 10.1208/aapsj070354
- By:
- Publication type:
- Article